Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression

BACKGROUND: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that has improved survival and central nervous system (CNS) outcomes in patients with non-small cell lung cancer (NSCLC) with activating EGFR mutations. However, little is known about the efficacy and safety of combin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Lung Cancer
Main Authors: White, Maya N, Piotrowska, Zofia, Stirling, Kevin, Liu, Stephen V, Banwait, Mandeep K, Cunanan, Kristen, Sequist, Lecia V, Wakelee, Heather A, Hausrath, Daniel, Neal, Joel W
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8205932/
https://ncbi.nlm.nih.gov/pubmed/33610453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2021.01.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados